# EDGAR Filing Document

**Accession Number:** 0001343009
**File Stem:** 0001683168-23-000628
**Filing Date:** 2023-2
**Character Count:** 4505
**Document Hash:** 1f315633cd664eef713e59ff5ca703b3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-23-000628.hdr.sgml**: 20230208

**ACCESSION NUMBER**: 0001683168-23-000628

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230131

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20230208

**DATE AS OF CHANGE**: 20230208

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CNBX Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001343009
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 203373669
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0831

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-52403
- **FILM NUMBER:** 23597110

**BUSINESS ADDRESS:**
- **STREET 1:** #3 BETHESDA METRO CENTER
- **STREET 2:** SUITE 700
- **CITY:** BETHESDA
- **STATE:** MD
- **ZIP:** 20814
- **BUSINESS PHONE:** 877-424-2429

**MAIL ADDRESS:**
- **STREET 1:** #3 BETHESDA METRO CENTER
- **STREET 2:** SUITE 700
- **CITY:** BETHESDA
- **STATE:** MD
- **ZIP:** 20814

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cannabics Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20140620

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** American Mining Corp
- **DATE OF NAME CHANGE:** 20110510

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Thrust Energy Corp.
- **DATE OF NAME CHANGE:** 20051031

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 31, 2023

**<u>CNBX PHARMACEUTICALS INC.</u>**

(Exact name of registrant as specified in its charter)

Nevada 000-52403 20-3373669 <br> (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

#3 Bethesda Metro Center

Suite 700

Bethesda, MD 20814

(Address of principal executive offices and Zip Code)

877 424-2429

(Registrant's telephone number, including area code)

______________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**ITEM 5.02 – DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.** 

On January 31<sup>st</sup>, 2023, Dr. Inbar Maymon Pomeranchik resigned from her position as a Director and Board Member. Her resignation was not the result of any disagreements with management.

Also on January 31<sup>st</sup>, 2023, Gil Feiler also presented his resignation as a Director and Board Member. His resignation was not the result of any disagreements with management.

**SIGNATURE**

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
|  | **CNBX PHARMACEUTICALS INC.** |
| Date: February 8, 2023 | By: *<u>/s/ Eyal Barad</u>* |
|  | Eyal Barad |
|  | Chief Executive Officer |

---